



# Neuronal resting membrane potential ( $rV_m$ )

- Neuronal membrane changes, electric activity, and synaptic connections creates behavior!
- $rV_m$  of neuron is “hyperpolarized” (more negative) relative to the extracellular side.
- $rV_m$  is ~ -65mV in many central neurons but can vary by +/-15mV.
- Membrane potential physiology also important to understand cardiovascular function.





# Resting membrane potential of neurons

- Hyperpolarized  $rV_m$  is established by...
- 1] Na/K pump  $\rightarrow 3\text{Na}^+ \text{out} / 2\text{K}^+ \text{in}$
- 2] membrane channels selectively permeable to certain ions “leak” K<sup>+</sup> and “leak” Na<sup>+</sup> channels.
- 40X more “leak” K than “leak” Na
- 3] unequal concentration of charged ions present in the intra vs. extracellular space determine direction and extent of ion flow.



# Voltage-gated sodium channel inactivation




**Membrane potential : Rest - depolarized - repolarize - rest**

Channel inactivation is produced by a separate part of the protein – “known as the inactivation gate”

Genetic mutations that affect the “inactivation gate” result in channels being open for too long – EPILEPSY!

Drugs have been developed to modify channel inactivation – speed up or slow down inactivation.

# 4 Phases of the AP



- 1. Rising phase = initial rapid **depolarization** – opening of **voltage-gated** Na<sup>+</sup> channels
- 2. Overshoot = portion of the AP that is depolarized > 0mV – opening, closing, inactivation of Na<sup>+</sup> channels and opening of K<sup>+</sup> channels.
- 3. Falling phase = rapid **hyperpolarization** – opening of **voltage gated** K<sup>+</sup> channels
- 4. Undershoot = portion of AP that is hyperpolarized past resting V<sub>m</sub> toward (E<sub>K+</sub>, -80mV) - closing of K<sup>+</sup> channels.

# Clinical correlates: Mechanisms of neurotoxins



## Tetrodotoxin (TTX)



- potent sodium channel blocker
- found in symbiotic bacteria in Pufferfish eg. genus *Lagocephalus*
- eaten in small amounts causes tingling and numbness of the mouth.
- eaten in large amounts can cause limb weakness, respiratory failure and cardiac arrest
- symptom onset varies from immediately to ~15mins

## Saxitoxin

- potent sodium channel blocker
- produced by dinoflagellates found in shellfish
- causes "paralytic shellfish poisoning"
- similar symptoms as in TTX poisoning


## $\alpha$ -dendrotoxin

- potent potassium channel blocker (Kv1)
- found in venom of the green mamba *Dendroaspis angusticeps*
- prolongs action potentials affecting neuro and cardiovascular function



# Mechanism of drug action: Lidocaine


- local anesthetic used for a variety of applications
- Sodium channel blocker
- can be applied topically as a cream
- can be injected directly into nerve, tissue, CSF



# Targeting VG Na channels for the treatment of pain (ex. after surgery).

Block action potentials in peripheral neurons (DRGs) carrying pain info to brain.

DRGs express voltage gated Na<sup>+</sup> channel (Nav1.8) that is not found in central neurons.



The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812 AUGUST 3, 2023 VOL. 389 NO. 5

Selective Inhibition of Na<sub>v</sub>1.8 with VX-548 for Acute Pain

J. Jones, D.J. Correll, S.M. Lechner, I. Jazic, X. Miao, D. Shaw, C. Simard, J.D. Osteen, B. Hare, A. Beaton, T. Bertoch, A. Buvanendran, A.S. Habib, L.J. Pizzi, R.A. Pollak, S.G. Weiner, C. Bozic, P. Negulescu, and P.F. White, for the VX21-548-101 and VX21-548-102 Trial Groups\*

## VX-548 now called suzetrigine (Journavx)

This site is intended for US residents only.

Patient Information Prescribing Information Important Safety Information JOURNAVX En Español For Healthcare Professionals

JOURNAVX™ (suzetrigine) 50mg tablet About JOURNAVX™ Savings and Support Resources Stay in Touch Share Your Story

How pain works

1 Pain signals are created by injury or surgery  
2 Pain signals move through the peripheral nervous system  
3 Pain is felt when pain signals reach the brain





How JOURNAVX works

1 Pain signals are created by injury or surgery  
2 JOURNAVX reduces pain signals before they reach the brain  
3 JOURNAVX works in the peripheral nervous system


# Glutamate synapses depolarize the postsynaptic neuron

\*\*\* Presynaptic voltage-gated



**Ca<sup>+</sup> channels** cause neurotransmitter release at the terminal.



- AP induced release of Glutamate into cleft
- Ionotropic glutamate receptors (AMPA) have a Na<sup>+</sup> pore. Glu binding opens channel and Na<sup>+</sup> rushes into the cell (some K<sup>+</sup> out of the cell).
- Depolarizes postsynaptic neuron which might contribute to AP generation in postsynaptic neuron.



# GABA synapses hyperpolarize the postsynaptic neuron



- AP induced release of GABA
- Ionotropic  $\text{GABA}_A$  receptors have a  $\text{Cl}^-$  pore.
- $\text{Cl}^-$  rushes into the cell due to concentration gradient
- Make it harder for the postsynaptic neuron to fire APs

Boldog et. al 2018




# Neurons are connected to one another at the synapse

- the site where neurons functionally communicate with one another



Electrical synapses:  
Gap junctions/Connexons



Direct ion & small molecule flow from one neuron to the other. Usually bidirectional.

Certain connexins expressed specific cell types.  
~30 disease due to connxin gene mutations








Figure 8.1

- E Mtui MD, G Gruener MD, MBA and P Dockery BSc, PhD
- Fitzgerald's Clinical Neuroanatomy and Neuroscience, 8; 85-101

# Gap junctions/Electrical synapses: no neurotransmitter used




Connors & Long 2004



- **Gap junctions allow direct ion & small molecule flow from one neuron to the other which can depolarize or hyperpolarize the postsynaptic neuron**
- **Amplitude attenuation of currents**
- **Usually bidirectional**
- **Fastest type of neural communication <1ms**
- **Can depolarize neurons**

# Patellar-tendon reflex:

## Great example of how neuronal connections and synaptic physiology creates behavior! Sensation & movement response




### Sensory pathway:

*Stretch-sensitive channels on 1a axons depolarize neuron and open voltage gated Na<sup>+</sup> channels causing AP.*

### Motor pathway:

*1a neuron synapses on motor neuron and releases Glu. Motor neuron fires an AP and releases Ach at quad muscle causing contraction.*



# *Synaptic transmission*

## Presynaptic

- Resting membrane potential
- Action potential generation
- Neurotransmitter synthesis
- Vesicle packaging of neurotransmitter
- Axonal calcium channels
- Reuptake of transmitter

## Synaptic cleft

- Neurotransmitter breakdown


## Postsynaptic

- Postsynaptic transmitter receptors  
    Ionotropic/metabotropic

*Synaptic mechanisms of disease*

# Lambert-Eaton Syndrome:


Auto-immune Disease of VGCC at the NMJ



Auto-antibodies to VG Ca channel

- Autoimmune disease characterized by the production of antibodies against voltage gated calcium channels (VGCC) present in NMJ
- Symptoms include muscle weakness throughout body especially limbs & face and autonomic symptoms.
- Weak muscles (weakness is often relieved for a short time after exercise or exertion)
- Trouble walking, climbing stairs or getting up from a chair, Tingling sensation in the hands or feet
- Eyelid drooping, Fatigue, Dry mouth or dry eyes
- Trouble speaking and swallowing
- Trouble breathing, Bladder and bowel changes
- Erectile dysfunction, Decreased sweating
- Weight loss
- Some pharmacological immunological treatments available to modulate VGCC function

# Myasthenia Gravis: Disease of AchR at the NMJ



- Autoimmune disease characterized by the production of antibodies against AchR
- Symptoms include muscle weakness throughout body especially limbs and face.
- Some pharmacological and immunological treatments available

New drug on the market: Vyvgart (FDA 2021)



<https://vyvgarthcp.com/gmg/about/moa>